康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

已收盘 03-24 16:08:20

53.800

+3.350

+6.64%

最高54.950	最低50.900	成交量645.48万
今开54.300	昨收50.450	日振幅8.03%
总市值160.86亿	流通市值160.86亿	总股本2.99亿
成交额3.44亿	换手率2.16%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":53.8,"timestamp":1774339700003,"preClose":50.45,"halted":0,"volume":6454799,"delay":0,"changeRate":0.06640237859266589,"floatShares":299000000,"shares":299000000,"eps":-1.966966,"marketStatus":"已收盘","change":3.35,"latestTime":"03-24 16:08:20","open":54.3,"high":54.95,"low":50.9,"amount":343879898,"amplitude":0.080278,"askPrice":53.85,"askSize":500,"bidPrice":53.8,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.945,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":50.45,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":5.167723,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2621068652","title":"超21亿美元抢滩TCE，吉利德收购康诺亚NewCo合作公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068652","media":"21世纪经济报道","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621068652?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:20","pubTimestamp":1774344000,"startTime":"0","endTime":"0","summary":"3月24日，康诺亚（02162.HK）发布公告称，公司NewCo合作企业OuroMedicines已与吉利德科学（简称“吉利德”，NASDQ：GILD）签署并购协议，吉利德将以并购方式收购OuroMedicines。此次交易总金额可达21.75亿美元，包括16.75亿美元首付款（可按惯例调整）和最高5亿美元里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682648353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682648353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1587","BK1574","02162","BK1161"],"gpt_icon":0},{"id":"2621032441","title":"吉利德拟以最高21.75亿美元收购Ouro Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2621032441","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621032441?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:18","pubTimestamp":1774322333,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1587","02162","BK1583","BK1574"],"gpt_icon":0},{"id":"2621038311","title":"康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2621038311","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621038311?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:47","pubTimestamp":1774306066,"startTime":"0","endTime":"0","summary":"紧随完成后，本集团将不再持有Ouro Medicines的任何股权。截至2025年12月31日，本集团自其于Ouro Medicines的股权录得未变现公允价值收益100万美元。董事认为，并购协议乃由买方与Ouro Medicines按公平原则磋商达成，按正常商业条款订立，属公平合理，而并购协议条款及其项下拟进行的交易符合本公司及其股东的整体利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B(02162)：持股公司Ouro Medicines被吉利德收购 预计获最高约3.2亿美元收益","news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1161","BK1574","02162"],"gpt_icon":0},{"id":"1154663615","title":"康诺亚-B(Keymed)拟向吉利德出售Ouro Medicines全部15%股权 最高获3.2 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154663615","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154663615?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:35","pubTimestamp":1774305343,"startTime":"0","endTime":"0","summary":"康诺亚-B24日在港交所发布公告称，其全资子公司一桥香港持有的Ouro Medicines约15%股权将于2026年3月23日以并购方式转让给吉利德科学公司。交易完成后，康诺亚-B不再持有Ouro Medicines任何权益。里程碑付款最高5 亿美元；总对价上限21.75 亿美元。合计最高3.2 亿美元。集团此前在Ouro Medicines股权上已录得未变现公允价值收益100万美元，本次交易的会计处理需待审计确认。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"1116881285","title":"康诺亚-B并购案预期收益：2.5亿美元首付款及其他收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1116881285","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116881285?lang=zh_cn&edition=full","pubTime":"2026-03-24 06:33","pubTimestamp":1774305194,"startTime":"0","endTime":"0","summary":"康诺亚生物医药（KeyMed Biosciences）近期披露的并购交易细节显示，该集团有望从此次合并中获得显著收益。交易结构包括一笔高达2.5亿美元的首期付款，以及其他潜在财务收益。这一并购安排预计将为集团带来可观的资金流入，进一步增强其财务实力和业务拓展能力。\n市场分析指出，此次并购不仅能够为康诺亚-B提供即时资金支持，还可能为其长期发展注入新的动力。交易的具体条款和后续收益分配机制，将成为投资者关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02162","BK1587","BK1583","BK1161"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中国银河：“十五五”首次将生物医药列为国家新兴支柱产业，持续发力研发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620203185?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0708995583.HKD","SG9999014674.SGD","BK4585","LU1969619763.USD","02359","06881","02268","399441","LU0417516571.SGD","LU0307460666.USD","LU0348767384.USD","06990","LU1770034418.SGD","LU2778985437.USD","HK0000306685.HKD","XBI","LU0052750758.USD","HK0000320223.HKD","LU2242644610.SGD","LU2476274720.SGD","BK1147","BK1161","BK4581","BK1588","IE00B543WZ88.USD","LU2125910500.SGD","LU0348825331.USD","02696","LU0348766576.USD","BK4588","601881","BK1564","LU2328871848.SGD","LU0348735423.USD","LU2476274308.USD","09995","LU0540923850.HKD","09926","HK0000306701.USD","BK1141","06160","161726","LU2045819591.USD","LU0196878994.USD","LU0588546209.SGD","LU1720050803.USD","02162","BK0276"],"gpt_icon":0},{"id":"2618791903","title":"港股异动 | 康诺亚-B(02162)再涨超3% CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618791903","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618791903?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:51","pubTimestamp":1773280266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B再涨超3%，截至发稿，涨2.21%，报55.5港元，成交额750.96万港元。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。阿斯利康已支付该里程碑款项。公开资料显示，康诺亚和乐普生物合资设立的KYM Biosciences Inc.于2023年2年与阿斯利康订立全球独家许可协议，授权阿斯利康在全球范围开发及商业化CMG901。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","BK1161","BK1587","LU1829250122.USD","LU2456880835.USD","LU0889565916.HKD","02162","BK1583","BK4007","LU0289739699.SGD","LU0320765992.SGD","LU2462157665.USD","BK4588","AZN","LU2417539215.USD","BK4585","LU2236285917.USD","VXUS","IE00B3T34201.USD","BK1574","LU0109394709.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2618792904","title":"每日卖空追踪 | 康诺亚-B 03月11日卖空量成交11.3万股，卖空比例为15.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618792904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618792904?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217828,"startTime":"0","endTime":"0","summary":"康诺亚-B北京时间03月11日，跌0.73%，卖空量成交11.3万股，较上一交易日减少62.46%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163351a460b683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163351a460b683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02162","BK1583","BK1587"],"gpt_icon":0},{"id":"2618974387","title":"康诺亚-B03月11日遭主力抛售261.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974387","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618974387?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216953,"startTime":"0","endTime":"0","summary":"03月11日, 康诺亚-B股价跌0.73%，报收54.30元，成交金额4030.9万元，换手率0.25%，振幅4.20%，量比0.34。康诺亚-B今日主力资金净流出261.9万元，连续3日净流出，上一交易日主力净流出655.1万元。该股近5个交易日上涨17.82%，主力资金累计净流出1018.6万元；近20日主力资金累计净流出912.7万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162019a460ab28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311162019a460ab28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02162","BK1583","BK1161","BK1587"],"gpt_icon":0},{"id":"2618290419","title":"中国KYM Biosciences：收到4500万美金MNC药企付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618290419","media":"药融圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618290419?lang=zh_cn&edition=full","pubTime":"2026-03-11 13:15","pubTimestamp":1773206151,"startTime":"0","endTime":"0","summary":"药融圈监测显示：中国药企KYM Biosciences Inc.于2023年2年与 阿斯利康 AstraZeneca订立全球独家许可协议，授权AstraZeneca在全球范围开发及商业化CMG901。基于当时的许可协议，KYM将获得6300万美元预付款和超过11亿美元的潜在额外开发和销售相关里程碑付款。目前，AstraZeneca已就AZD0901治疗晚期实体瘤开展了多项全球临床研究，适应症含括胃癌、胰腺癌及胆道癌等等。近期在2026年3月10日，根据许可协议条款及条件，临床研究进展触发总金额4500万美元里程碑付款，已经到账。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311133823a4604bcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311133823a4604bcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02162","BK1583","BK1587"],"gpt_icon":0},{"id":"2618993297","title":"康诺亚收到4500万美元里程碑付款；辉瑞全球首创三抗II期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2618993297","media":"氨基观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618993297?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:40","pubTimestamp":1773142800,"startTime":"0","endTime":"0","summary":"根据许可协议条款及条件，该研究进展触发总金额4500万美元里程碑付款。辉瑞全球首创三抗II期研究成功。/ 01 /市场速递1）康诺亚收到4500万美元里程碑付款3月10日，康诺亚宣布，公司核心产品Claudin18.2 ADC CMG901在全球授权合作伙伴阿斯利康推动下，已启动一项III期临床研究，并完成了首例受试者给药。2）辉瑞全球首创三抗II期研究成功3月9日，辉瑞宣布，在研IL-4/IL-13/TSLP三特异性抗体Tilrekimig治疗中重度特应性皮炎的II期研究取得了积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310203649a45ea18a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310203649a45ea18a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1587","BK1583","BK1574","02162"],"gpt_icon":0},{"id":"2618939295","title":"康诺亚CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939295","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939295?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:18","pubTimestamp":1773137907,"startTime":"0","endTime":"0","summary":"北京商报讯3月10日，康诺亚发布公告，更新了与AstraZeneca（阿斯利康）就核心产品CMG901（AZD0901）合作的最新情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667582417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667582417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","LU0058720904.USD","LU0289739699.SGD","BK4585","02162","BK1574","BK1587","BK4588","LU0320765992.SGD","AZN","BK4568","LU2417539215.USD","BK1161","IE00B3T34201.USD","LU1829250122.USD","LU0889565916.HKD","LU0109394709.USD","BK1583","LU2236285917.USD","LU2462157665.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"1129494914","title":"康诺亚-B：阿斯利康制药启动AZD0901治疗晚期胃癌的三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1129494914","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129494914?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:07","pubTimestamp":1773133626,"startTime":"0","endTime":"0","summary":"康诺亚-B（KeyMed Biosciences Inc）近日宣布，其合作伙伴阿斯利康制药（AstraZeneca PLC）已正式启动AZD0901针对晚期胃癌患者的三期临床研究。这一关键性试验的开展，标志着该创新药物在胃癌治疗领域的研发进程迈入了决定性阶段。\nAZD0901作为一款备受关注的候选药物，其疗效与安全性将通过此项大规模临床试验得到进一步验证。该研究的启动不仅为晚期胃癌患者带来了新的治疗希望，也预示着相关领域的治疗格局可能迎来重要变革。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823399737.USD","LU0972486137.USD","LU2112291526.USD","LU0757432116.USD","LU1880407215.USD","LU0310799852.SGD","SG9999013999.USD","LU1814569148.SGD","LU2539964713.USD","LU0266013472.USD","LU2293690249.USD","LU1003076772.USD","LU1481600234.SGD","LU0553294199.USD","LU0203345920.USD","LU0784385840.USD","LU1015430645.USD","LU1267930227.SGD","BK1574","LU1267930573.SGD","LU1983299246.USD","LU0310800379.SGD","LU0889565080.SGD","LU0203347892.USD","LU0557290698.USD","LU0128525929.USD","LU0128525689.USD","LU0738911758.USD","IE00B2B36J28.USD","LU0661504455.SGD","LU0964806797.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK5011","LU0052756011.USD","LU0827474353.SGD","LU1487256676.USD","SGXZ57979304.SGD","LU0545039389.USD","BK1583","LU2089984988.USD","LU1481599808.USD","LU1003077747.HKD","LU1078025761.USD","LU0029864427.USD","LU2324357040.USD","LU1267930490.SGD","LU0920840948.USD","LU2089283258.USD","LU1019632923.USD","LU0047473722.SGD","LU1051770623.HKD","LU1496350171.SGD","LU1496350502.SGD","LU0496365809.HKD","LU0949170426.SGD","LU1057294990.SGD","LU1064927863.SGD","AZN.UK","LU0011850046.USD","LU1989772923.USD","LU0640478417.SGD","LU0882574055.USD","IE0034235188.USD","IE00B3T34201.USD","LU0171293334.USD","LU0211328371.USD","LU1261432733.SGD","LU1170363599.USD","LU0784383803.USD","LU0887340254.USD","LU2089284900.SGD","LU0784384876.USD","LU2293690082.USD","LU1119994496.HKD","LU0823416689.USD","LU2468319806.SGD","LU0708994859.HKD","IE00BKPKM643.USD","LU1019634622.SGD","LU1104425308.USD","LU1989771016.USD","LU0058720904.USD","LU0345777659.USD","LU0122379950.USD","LU0857590862.USD","LU0345777147.USD","LU0976567544.SGD","IE0002141913.USD","SG9999001176.USD","LU0920783379.SGD","LU1061106388.HKD","02162","BK1587","LU1291159041.SGD","BK1161","LU0575583348.USD","LU0997586432.USD","IE00BJJMRZ35.SGD","LU0077335932.USD","LU0792757196.USD","IE0009355771.USD","LU0158827948.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU2023251221.USD","LU0211327993.USD","LU2091194634.USD","SG9999001176.SGD","LU1084165304.USD","LU0957799991.USD","LU0432979614.USD","LU0114720955.EUR","LU0969580561.USD","LU0289739699.SGD","LU1301847155.USD","LU2108987350.USD","LU1153585028.USD","LU1267930813.SGD","LU1153584641.USD","LU0784385170.HKD","LU2279689827.SGD","LU0211326839.USD","LU0949170772.SGD","LU1880407132.USD","LU0310800965.SGD","LU1023059063.AUD","LU0963555726.SGD","LU0960981461.USD","LU1046234339.USD","03165","LU0889566641.SGD","LU0499090636.EUR","LU0526926950.USD","LU1989772840.SGD","LU2133065610.SGD","LU2114397693.USD","LU0211326755.USD","LU0047473722.EUR"],"gpt_icon":0},{"id":"2618335539","title":"康诺亚-B(02162)：AstraZeneca已启动一项有关CMG901 (AZD0901)的临床试验，并完成了首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2618335539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618335539?lang=zh_cn&edition=full","pubTime":"2026-03-10 17:06","pubTimestamp":1773133566,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，就有关集团与AstraZeneca AB就核心产品CMG901合作的最新情况。截至本公告日期，AstraZeneca宣布其已启动一项sonesitatug vedotin 联合卡培他滨联合或不联合rilvegostomig一线治疗Claudin 18.2阳性、HER2阴性的晚期╱转移性胃癌、胃食管结合部癌或食管腺癌的多中心、随机对照、III期临床研究，并完成了首例受试者给药。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。集团已收到AstraZeneca付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1161","BK1574","02162"],"gpt_icon":0},{"id":"2618646757","title":"每日卖空追踪 | 康诺亚-B 03月09日卖空量成交8.55万股，卖空比例为5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646757","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646757?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045028,"startTime":"0","endTime":"0","summary":"康诺亚-B北京时间03月09日，跌2.48%，卖空量成交8.55万股，较上一交易日减少62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163349a45ae7b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163349a45ae7b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02162","BK1587","BK1583"],"gpt_icon":0},{"id":"2618756646","title":"康诺亚-B盘中异动 股价大跌6.56%报48.960港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618756646","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618756646?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:30","pubTimestamp":1773019837,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时30分，康诺亚-B股票出现异动，股价大幅下跌6.56%。截至发稿，该股报48.960港元/股，成交量10000股，换手率0.00%，振幅4.27%。资金方面，该股资金流入10.24万港元，流出19.584万港元。最近的财报数据显示，该股实现营业收入5.47亿港元，净利润-8,645.54万港元，每股收益-0.33港元，毛利5.10亿港元，市盈率-27.41倍。康诺亚-B股票所在的生物技术行业中，整体跌幅为1.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093037a6b081f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093037a6b081f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02162","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2618617106","title":"国产创新药持续发力，AD治疗领域将迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617106","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618617106?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:29","pubTimestamp":1773019791,"startTime":"0","endTime":"0","summary":"据悉，继司普奇拜单抗之后多款国产药物也加速推进临床，并将迎来一波上市高潮。未来随着这些产品的获批上市，AD药物领域将迎来新的用药选择。随着多款新药的陆续上市，这不仅将打破国外药物垄断、降低患者用药成本，更将推动我国AD治疗的发展。未来，在政策支持与企业创新的双重驱动下，国内AD药物研发将持续突破，为全球特应性皮炎治疗贡献中国力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348767384.USD","09926","06978","LU2488822045.USD","LU0417516902.SGD","01276","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2476274308.USD","BK1574","LU0348783233.USD","LU2778985437.USD","LU0634319403.HKD","LU0417516738.SGD","LU0417516571.SGD","00867","LU0348784397.USD","LU2476274720.SGD","LU1720050803.USD","LU0561508036.HKD","LU1961090484.USD","LU0348766576.USD","02162","BK1161","LU0348825331.USD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU2399975544.HKD"],"gpt_icon":0},{"id":"2617066845","title":"创新药板块强势 三生制药(01530)涨9.83% 机构指业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066845","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066845?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:41","pubTimestamp":1772764875,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块强势，三生制药 涨9.83%，基石药业-B涨6.84%，荣昌生物涨6.31%，映恩生物-B涨5.98%，四环医药涨5.76%，恒瑞医药涨5.77%，君圣泰医药-B涨5.58%，康诺亚-B涨5.31%，复宏汉霖涨5.02%。交银国际表示，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","HK0000306685.HKD","BK1191","09995","02616","02162","BK1583","02696","LU1969619763.USD","09606","01530","HK0000252160.HKD","LU2543165471.USD","06978","HK0000320264.USD","BK1515","02511","BK1587","BK1161","LU2328871848.SGD","HK0000165453.HKD","LU0359201612.USD","LU0359201885.HKD","HK0000306701.USD","LU1023057109.AUD","HK0000320223.HKD","LU0359202008.SGD","HK0000252152.HKD","BK1574","HK0000500386.USD","00460","01276","159992","BK1593"],"gpt_icon":0},{"id":"2617509717","title":"康诺亚-B盘中异动 早盘大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617509717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617509717?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:51","pubTimestamp":1772761876,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘09时51分，康诺亚-B股票出现异动，股价急速拉升5.00%。截至发稿，该股报50.400港元/股，成交量23.35万股，换手率0.08%，振幅5.75%。机构评级方面，在所有2家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。康诺亚-B股票所在的生物技术行业中，整体涨幅为0.54%。其相关个股中，宜明昂科-B、科笛-B、康诺亚-B涨幅较大，振幅较大的相关个股有银诺医药-B、映恩生物-B、MIRXES-B，振幅分别为9.94%、8.52%、8.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306095116a451f5dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306095116a451f5dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","02162","BK1587"],"gpt_icon":0},{"id":"2617050978","title":"康方生物、三生国健等，扎堆申报！","url":"https://stock-news.laohu8.com/highlight/detail?id=2617050978","media":"药通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617050978?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:32","pubTimestamp":1772710373,"startTime":"0","endTime":"0","summary":"近日，康方生物、三生国健等IL-4Rα抗体迎来新进展。除了康方生物、三生国健，国内已有多款国产IL-4Rα单抗进入上市冲刺阶段，形成了群雄逐鹿的竞争格局。其中，康诺亚/石药集团的司普奇拜单抗已获批上市；宝船生物/麦济生物的柯美奇拜单抗、康乃德的乐德奇拜单抗、智翔金泰的泰利奇拜单抗等也相继申报上市，各自将凭借差异化优势抢占市场先机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305210329a6a6d362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305210329a6a6d362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","LU0348783233.USD","LU0348735423.USD","LU0561508036.HKD","LU2476274720.SGD","LU0417516571.SGD","BK1587","LU2488822045.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0348827113.USD","LU0540923850.HKD","09926","LU1720050803.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","BK1574","02162","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU0417516902.SGD","LU2399975544.HKD","BK1583","LU2476274308.USD","LU0348766576.USD","LU1794554557.SGD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0718},{"period":"1month","weight":-0.0718},{"period":"3month","weight":-0.0811},{"period":"6month","weight":-0.2874},{"period":"1year","weight":0.3207},{"period":"ytd","weight":-0.0561}],"compareEarnings":[{"period":"1week","weight":-0.0562},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.054},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0292},{"period":"ytd","weight":-0.0487}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.2,"avgChangeRate":-0.020268},{"month":4,"riseRate":1,"avgChangeRate":0.037917},{"month":5,"riseRate":0.25,"avgChangeRate":-0.097555},{"month":6,"riseRate":1,"avgChangeRate":0.124436},{"month":7,"riseRate":0.5,"avgChangeRate":0.132155},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}